ENZN Insider Trading Activity and SEC Form 4 Filings
ENZN insider trading summary
No open-market insider purchases or sales of Enzon Pharmaceuticals, Inc. (ENZN) have been reported on SEC Form 4 in the past 12 months.
Latest ENZN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 16, 2023 | Randolph C Read | Director | Buy | $12K (84,550 @ $0.14) |
| Jun 14, 2023 | Randolph C Read | Director | Buy | $2K (15,000 @ $0.13) |
| Aug 13, 2021 | Myrexis, Inc. | 10% Owner | Sell | $19K (50,000 @ $0.39) |
| Aug 13, 2021 | Xstelos Corp. | 10% Owner | Sell | $22K (57,500 @ $0.39) |
| Aug 13, 2021 | Jonathan Couchman | 10% Owner | Sell | $22K (57,500 @ $0.39) |
| Aug 13, 2021 | Xstelos Corp. | 10% Owner | Sell | $19K (50,000 @ $0.39) |
| Aug 13, 2021 | Jonathan Couchman | 10% Owner | Sell | $19K (50,000 @ $0.39) |
| Aug 13, 2021 | Couchman Family Fund | 10% Owner | Sell | $22K (57,500 @ $0.39) |
| Aug 13, 2021 | Myrexis, Inc. | 10% Owner | Sell | $22K (57,500 @ $0.39) |
| Aug 13, 2021 | Couchman Family Fund | 10% Owner | Sell | $19K (50,000 @ $0.39) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.